2.2200
08-1月-25 16:45:00
15 分の遅延
株式
-0.0400
-1.77%
本日の幅
2.1600 - 2.3392
ISIN
N/A
ソース
NASDAQ
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
18 4 2024 07:00:00 提供 Nasdaq GlobeNewswire
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
02 4 2024 07:00:00 提供 Nasdaq GlobeNewswire
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
25 3 2024 07:06:46 提供 Nasdaq GlobeNewswire